DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

June 18, 2018 Agreement with Glooko Provides Broad Access of Insulin Pump Therapy Optimization to Physicians, Patients and Payers PETAH TIKVA, Israel, June 18, 2018 /PRNewswire/ — DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that the U.S Food and Drug Administration